The management of high-risk gestational trophoblastic tumours (GTT)

International Journal of Gynecology and Obstetrics

Volumn 60, Issue SUPPL.1, 1998, Pages

  Newlands, E S ^a   Bower, M ^a   Holden, L ^a   Short, D ^a   Brock, C ^a   Rustin, G J S ^a   Begent, R H J ^a   Bagshawe, K D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; EMA CO PROTOCOL; EMA-CO PROTOCOL; ETOPOSIDE; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; PREGNANCY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; TROPHOBLASTIC TUMOR; UTERUS CANCER;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FEMALE; HUMANS; METHOTREXATE; MIDDLE AGED; PREGNANCY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TROPHOBLASTIC NEOPLASMS; UTERINE NEOPLASMS; VINCRISTINE;

EID: 0002486115     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(98)80007-6     Document Type: Article

References (13)

1. Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976; 38:1 373-1385.
2. World Health Organisation Scientific Group on Gestational Trophoblastic Diseases: Gestational Trophoblastic Diseases. Geneva WHO 1983.
3. Newlands E, Bagshawe K: Antitumour activity of epipodophylin derivative VP16-213 (etoposide: NSC-141540) in gestational choriocarcinoma. Bur J Cancer 1980; 16: 401-405.
4. Newlands ES, Bagshawe KD, Begent RHJ et al. Developments in chemotherapy for medium and high-risk patients with gestational trophoblastic tumours (1974-1984). Br J Obstet Gynecol 1986; 93: 63-69.
5. Newlands ES, Bagshawe KD, Begent RHJ et al. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regime in high-risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynecol 1991; 98: 550-557.
6. Bolis G, Belloni C, Bonazzi C et al. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). Obstet Gynecol Surv 1989; 44: 394-395.
7. Schink J, Singh D, Rademaker A et al. Etoposide, methotrexate, actionomycin D, cyclophosphamide and vincristine for the treatment of metastatic high-risk gestational trophoblastic disease. Obstet Gynecol 1992; 80:817.
8. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
9. Peto R, Pike M, Armitage P et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: II analysis and examples. Br J Cancer 1977; 35:1-39.
10. Cox D. Regression models and life tables. J Royal Stat Soc B 1972; 34: 187-220.
11. Berkowitz RS, Bernstein MR, Laborde O et al. Subsequent pregnancy experiences in patients with gestational trophoblastic disease. J Reprod Medicine 1994; 39: 228-232.
12. Crawford R, Newlands E, Rustin G et al. Gestational trophoblastic disease with liver metastases: The charing cross experience. Br J Obstet Gynecol 1997; 104: 105-109.
13. Rustin G, Newlands E, Lutz JM et al. Combination but not single agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996;14